Neurelis has completed the subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.
Through the collaboration with the University of Minnesota and James Cloyd, PharmD, Neurelis has partnered with clinical researchers regarding the nasal delivery of benzodiazepines. Results from this important study are expected in June.
"Neurelis has incorporated proprietary technologies to develop intranasal diazepam formulations that can be delivered with a standard sprayer to patients experiencing acute breakthrough seizures. These intranasal product formulations seek to address the need for a convenient and effective therapy that could help reduce acute breakthrough seizures and avoid the need for costly emergency room visits," stated David Hale, chairman of Neurelis.